Intelligent Bio Solutions (Intelligent Bio Solutions) Debt-to-Equity : 0.33 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Debt-to-Equity?

Intelligent Bio Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.62 Mil. Intelligent Bio Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.46 Mil. Intelligent Bio Solutions's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.28 Mil. Intelligent Bio Solutions's debt to equity for the quarter that ended in Dec. 2023 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intelligent Bio Solutions's Debt-to-Equity or its related term are showing as below:

INBS' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.7 Med: -0.92 Max: 0.86
Current: 0.33

During the past 7 years, the highest Debt-to-Equity Ratio of Intelligent Bio Solutions was 0.86. The lowest was -1.70. And the median was -0.92.

INBS's Debt-to-Equity is ranked worse than
61.52% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs INBS: 0.33

Intelligent Bio Solutions Debt-to-Equity Historical Data

The historical data trend for Intelligent Bio Solutions's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions Debt-to-Equity Chart

Intelligent Bio Solutions Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

-1.29

-0.99

0.35

Intelligent Bio Solutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.18	0.28	0.35	0.86	0.33

Competitive Comparison of Intelligent Bio Solutions's Debt-to-Equity

For the Medical Devices subindustry, Intelligent Bio Solutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelligent Bio Solutions's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intelligent Bio Solutions's Debt-to-Equity falls into.

Intelligent Bio Solutions Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intelligent Bio Solutions's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.577	+	0.759)	/	3.799
	=	0.35

Intelligent Bio Solutions's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.621	+	0.46)	/	3.28
	=	0.33

Intelligent Bio Solutions (NAS:INBS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Intelligent Bio Solutions Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

12Q:Germany

Address

57th Street, 142 West, 11th Floor, New York, NY, USA, 10019

Website

https://www.gbs.inc

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

Executives

Harry Simeonidis	director, officer: CEO, President	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins	director	P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg	director	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris	officer: Chief Financial Officer	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd	10 percent owner	LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers	director	1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher	director	C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017